Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Moretz

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Pulmonary Therapy|March 17, 2021
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary DiseaseDavid Slade, Riju Ray, Chad Moretz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 20, 2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort studyChad Moretz, Lucie Sharpsten, Lindsay Gs Bengtson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2019
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterolChad Moretz, Lindsay Gs Bengtson, Lucie Sharpsten, et al.
Oncology and Therapy|June 21, 2026
Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene PanelsPaul Spin, Bela Bapat, Chad Moretz, et al.
The American Journal of Managed Care|February 20, 2025
Medical policy determinations for pharmacogenetic tests among US health plansJai N Patel, Lena Chaihorsky, Olivia M Dong, et al.
The American Journal of Managed Care|April 17, 2015
Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiariesLeslie Hazel-Fernandez, Yong Li, Damion Nero, et al.
Current Medical Research and Opinion|July 19, 2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United StatesJay P Bae, Douglas E Faries, Frank R Ernst, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 9, 2016
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrelJay P Bae, Douglas E Faries, Frank R Ernst, et al.
Drugs & Aging|October 29, 2015
Erratum to: Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United StatesS Lane Slabaugh, Yihua Xu, Jane N Stacy, et al.
Drugs & Aging|January 10, 2015
Antidiabetic treatment patterns in a medicare advantage population in the United StatesS Lane Slabaugh, Yihua Xu, Jane N Stacy, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Pulmonary Therapy|March 17, 2021
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary DiseaseDavid Slade, Riju Ray, Chad Moretz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 20, 2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort studyChad Moretz, Lucie Sharpsten, Lindsay Gs Bengtson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2019
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterolChad Moretz, Lindsay Gs Bengtson, Lucie Sharpsten, et al.
Oncology and Therapy|June 21, 2026
Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene PanelsPaul Spin, Bela Bapat, Chad Moretz, et al.
The American Journal of Managed Care|February 20, 2025
Medical policy determinations for pharmacogenetic tests among US health plansJai N Patel, Lena Chaihorsky, Olivia M Dong, et al.
The American Journal of Managed Care|April 17, 2015
Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiariesLeslie Hazel-Fernandez, Yong Li, Damion Nero, et al.
Current Medical Research and Opinion|July 19, 2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United StatesJay P Bae, Douglas E Faries, Frank R Ernst, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 9, 2016
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrelJay P Bae, Douglas E Faries, Frank R Ernst, et al.
Drugs & Aging|October 29, 2015
Erratum to: Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United StatesS Lane Slabaugh, Yihua Xu, Jane N Stacy, et al.
Drugs & Aging|January 10, 2015
Antidiabetic treatment patterns in a medicare advantage population in the United StatesS Lane Slabaugh, Yihua Xu, Jane N Stacy, et al.
Pageof 5